US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
NRX Pharmaceuticals Inc (NRXP)
NRX Pharmaceuticals Inc (NRXP) ニュース

NRXP

NRX Pharmaceuticals (NRXP)

NRX Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NRXP

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/10	21 : 30	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/05/28	21 : 30	PR Newswire (US)	NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipola	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/05/15	05 : 01	PR Newswire (US)	NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/05/08	21 : 30	PR Newswire (US)	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/05/08	05 : 01	PR Newswire (US)	NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/05/06	21 : 30	PR Newswire (US)	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/30	21 : 30	PR Newswire (US)	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/18	21 : 32	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/18	21 : 30	PR Newswire (US)	NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/18	05 : 45	PR Newswire (US)	NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/17	21 : 30	PR Newswire (US)	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/15	21 : 30	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/08	21 : 30	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/04/01	21 : 28	PR Newswire (US)	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/28	21 : 03	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/28	21 : 00	PR Newswire (US)	NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/27	05 : 03	PR Newswire (US)	UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/25	21 : 30	PR Newswire (US)	NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/22	05 : 02	PR Newswire (US)	NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/22	02 : 57	PR Newswire (US)	NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/12	20 : 49	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/12	06 : 16	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/11	21 : 30	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/07	06 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/04	22 : 30	PR Newswire (US)	NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/03/01	22 : 30	PR Newswire (US)	NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/02/29	07 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/02/29	00 : 40	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/02/28	00 : 49	PR Newswire (US)	/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./	NASDAQ:NRXP	NRX Pharmaceuticals Inc
2024/02/27	22 : 54	PR Newswire (US)	NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 million	NASDAQ:NRXP	NRX Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:NRXP

1 2 3 4 5 6 7 8 9 次へ >>

JP Morgan Chase

Health Care Select Sector

Bank of America

Deutsche Telekom (QX)

Financial Select Sector

Verizon Communications

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約